Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

Phase 2

Terminated

• Conditions: Obesity

• Registration Number: NCT00367783
• Lead Sponsor: Pfizer

Brief Summary

The purpose of this study is to determine whether CP-741,952 is effective in the treatment of obesity and to determine 12 week safety and toleration.

Detailed Description

Following review of the preliminary data from completed study A7081004, the development program for CP-741,952 was terminated on 15 March 2007. Primary reasons for program termination included a lack of significant efficacy at all doses investigated and an increased incidence of mild to moderate elevations in serum transaminases, primarily alanine aminotransferase (ALT), and liver fat content, in treated compared to placebo subjects. A synopsis will be created and will include greater detail on these findings.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2006-05-30
• Study Start: 2006-06
• Study First Submitted QC: 2006-08-21
• Study First Posted: 2006-08-23
• Study Completion: 2007-04
• Status Verified: 2011-07
• Last Update Submitted: 2011-07-29
• Last Update Posted: 2011-08-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• BMI of 30-40 kg/m2

Read More

Exclusion Criteria

• Women of childbearing potential

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Weight Loss, toleration, safety

Secondary Outcome Measures

Name	Time	Method
Waist Circumference, serum lipids

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 San Antonio, Texas, United States